KIORA PHARMACEUTICALS, INC. Contingent Consideration Classified as Equity, Fair Value Disclosure
KIORA PHARMACEUTICALS, INC. (KPRX) had Contingent Consideration Classified as Equity, Fair Value Disclosure of $3.04 million as of 2026-06-30, per its 10-Q filed 2026-08-07.
Financial Statements › Notes › Fair Value Disclosures › Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis
us-gaap:ContingentConsiderationClassifiedAsEquityFairValueDisclosure · last filed 2026-08-07
- 2026-06-30: Contingent Consideration Classified as Equity, Fair Value Disclosure $3.04M.
- 2026-03-31: Contingent Consideration Classified as Equity, Fair Value Disclosure $2.95M.
- 2025-09-30: Contingent Consideration Classified as Equity, Fair Value Disclosure $2.88M.
- 2025-06-30: Contingent Consideration Classified as Equity, Fair Value Disclosure $4.60M.
| Period end | Contingent Consideration Classified as Equity, Fair Value Disclosure |
|---|---|
| 2026-06-30 | $3.04M 10-Q · filed 2026-08-07 |
| 2026-03-31 | $2.95M 10-Q · filed 2026-05-08 |
| 2025-09-30 | $2.88M 10-Q · filed 2025-11-07 |
| 2025-06-30 | $4.60M 10-Q · filed 2025-08-08 |
| 2025-03-31 | $4.47M 10-Q · filed 2025-05-09 |
| 2024-09-30 | $4.13M 10-Q · filed 2024-11-08 |
| 2024-06-30 | $5.24M 10-Q · filed 2024-08-09 |
| 2024-03-31 | $5.12M 10-Q · filed 2024-05-10 |
| 2023-09-30 | $5.50M 10-Q · filed 2023-11-09 |
| 2023-06-30 | $4.00M 10-Q · filed 2023-08-08 |
| 2023-03-31 | $3.84M 10-Q · filed 2023-05-09 |
| 2022-09-30 | $3.65M 10-Q · filed 2022-11-09 |
| 2022-06-30 | $3.32M 10-Q · filed 2022-08-12 |
| 2022-03-31 | $3.28M 10-Q · filed 2022-07-08 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Scienture Holdings, Inc. (SCNX) | United States | $0.012B | -0.38 |
| Phio Pharmaceuticals Corp. (PHIO) | United States | $0.012B | -0.92 |
| ADIAL PHARMACEUTICALS, INC. (ADIL) | United States | $0.012B | |
| Dare Bioscience, Inc. (DARE) | United States | $0.011B | |
| BIOVIE INC. (BIVI) | United States | $0.012B | |
| Aspire Biopharma Holdings, Inc. (ASBP) | United States | $0.012B | -0.60 |
| Tempest Therapeutics, Inc. (TPST) | United States | $0.013B | |
| Moleculin Biotech, Inc. (MBRX) | United States | $0.011B | |
| MetaVia Inc. (MTVA) | United States | $0.011B | -0.65 |
| KALA BIO, Inc. (KALA) | United States | $0.011B | -3.33 |